Dr Elizabeth Fagan
Elizabeth Fagan, M.D. has served as a member of our board of directors since April 2017. Dr. Fagan has been an independent consultant and hepatologist to the biotechnology and biopharmaceutical industry with a focus on clinical drug development, including anti-fibrotic agents and drug-induced liver injury, since April 2015. Dr. Fagan has also been a professor of Internal Medicine and Pediatrics at Rush-Presbyterian-St. Luke’s Medical Center since 1994 and an adjunct professor since 2013. She brings to Perspectum over 15 years’ experience in clinical drug development and medical affairs and other medical and scientific leadership roles in the biotechnology and pharmaceutical space. Dr. Fagen previously served as a member of the board of directors of biopharmaceutical companies InterMune, Inc. from 2011 to 2015, Gilead Sciences, Inc. from 2008 to 2010, Avexa Ltd. from 2007 to 2008, Encysive Pharmaceuticals Inc. from 2005 to 2007 and Tanox, Inc. from 2002 to 2005.
Dr. Fagan is a transatlantic academic physician with more than 40 years of experience in clinical medicine and research in adult and pediatric hepatology and internal medicine. She has extensively lectured on viral hepatitis, liver disease and health issues across the U.K., Europe, Nigeria, the Indian sub- continent, the Middle East, Kuala Lumpur, Singapore, Hong Kong, Australia and New Zealand. Dr. Fagan has published over 100 papers, of which 50 are peer reviewed in journals including; the New England Journal of Medicine, the Lancet and the Journal of Hepatology. She has written over 20 book chapters and reviews. Her book on viral hepatitis was commissioned in the United Kingdom and the United States. Dr. Fagan received a BSc. In Physiology, a MSc. In Immunology and an M.D. in Molecular Virology from King’s College London.